• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Welldoc says CGM, digital health platform combination provides better glycemic outcomes

April 28, 2022 By Sean Whooley

welldocWelldoc said that its combination of real-time continuous glucose monitoring (CGM) and digital health impacts glucose control in type 2 diabetes.

Columbia, Maryland-based Welldoc presented data at the Conference on Advanced Technologies & Treatments for Diabetes (ATTD) from a study of real-time CGM and digital health in individuals with type 2 diabetes not treated with insulin. For all participants and subgroups examined, time in range and the glucose management indicator (GMI) improved significantly, demonstrating that the combination could improve type 2 diabetes management and glycemic control.

The company combines the Dexcom G6 CGM with its BlueStar digital health platform, thanks to a partnership expansion agreed upon by the companies in April 2021. Three patient cohorts were evaluated with this combination, with data showing that the intermediate users’ cohort improved the most, increasing their time in range by 32% and GMI by 1.4.

BlueStar, an FDA-cleared software as a medical device offering, provides actionable insights that inform care plans and encourage better total health outcomes. Self-management behavior coaching on BlueStar includes parameters related to food, activity, sleep, symptoms and medication taking.

“We are encouraged by the improvements we observed in glycemic outcomes and believe the findings demonstrate the significant potential that real-time CGM data integration brings to our digital health offering,” Welldoc CMO Dr. Mansur E. Shomali said in a news release. “As we improve our understanding of digital health engagement needs in relation to CGM, we move closer toward a care model that captures ‘whole person care’ in ways not achieved to date.”

Filed Under: Clinical Trials, Diabetes, Drug-Device Combinations, Featured, Patient Monitoring, Technology Tagged With: Dexcom, welldoc

IN CASE YOU MISSED IT

  • Medtronic enrolls first patient in study for Onyx liquid embolic system
  • BD issues voluntary recall on certain Alaris infusion pump modules
  • Sequel Med Tech expects full twiist launch in the fall
  • Insulet hires new chief HR officer from J&J
  • Breakthrough T1D, Mattel debut Barbie doll with type 1 diabetes

About Sean Whooley

Sean Whooley is an associate editor who mainly produces work for MassDevice, Medical Design & Outsourcing and Drug Delivery Business News. He received a bachelor's degree in multiplatform journalism from the University of Maryland, College Park. You can connect with him on LinkedIn or email him at swhooley@wtwhmedia.com.

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS